Autobahn Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:45 p.m. ET.
About Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neurodegenerative clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company's pipeline is led by ABX-002, a thyroid hormone receptor beta (TR?) agonist being developed as a potential adjunctive treatment for people with major depressive disorder, including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.
A report from GDToday:
On the evening of May 3, 2024, the Guangzhou Opera House dazzled audiences with the performance of "Marco Polo," a captivating opera commissioned by the esteemed venue. In order to commemorate the 700th anniversary of the...
Garrett Smith, Founder and CEO of Community Capital Technology Inc. ("Community Capital"), will be attending the Milken Institute Global Conference ("MI Global") May 5-8, 2024 in Los Angeles. The event brings together global executives and...
Quarterhill Inc. ("Quarterhill" or the "Company") , a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS")...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review...
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...
F5 announced that it has been singled out as a visionary in API security for its F5 Distributed Cloud Web App and API Protection (WAAP) in Enterprise Management Associates' Vendor Vision 2024 report. The report highlights "must see" security...
